Research & Development: Page 57
-
Talent Pool
Pharmaceutical POOL Dr. Anirvan GHOSH Roche Selects Head of CNS Discovery Global healthcare company Roche has named Anirvan Ghosh, Ph.D., head of discovery for central nervous system (CNS). Dr. Ghosh is based at Roche’s pharma research and early development organization in Basel, Switzerland, an...
By PharmaVoice Team • April 25, 2011 -
PharmaTrax
Sales, Marketing, and R&D Trends from Industry Analysts Featured Briefs: R&D Productivity Measures Consistently Undervalued Generics Firms Turning to M&A for Market Foothold Sidebar: Top 10 New Product Approvals in 2010 Specialty, Hospital Sales Forces Anticipate Double-Digit Growth P...
By PharmaVoice Team • April 25, 2011 -
Explore the Trendline➔
Stock via Getty ImagesTrendlineClinical trial diversity
As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.
By PharmaVoice staff -
Letter from the Editor
The mHealth Revolution The Statistics are staggering. According to a report by research2guidance, by 2015 one in five people around the world will have a smartphone. Another report states that mobile app revenue is expected to reach $35 billion by 2014. Finally, company investment in mobile phone...
By Taren Grom • April 25, 2011 -
Showcase Feature — IRBs Watching the Protectors
Ever-changing clinical-trial regulations and continued growth in multicenter and international studies have resulted in an exponential increase in the volume of data generated for IRB review, including large numbers of individual adverse event (AE) reports, which often lack the context and detail...
By Carolyn Gretton • March 28, 2011 -
Privyet! Russia: Growth and Opportunity
With its promise of expansion, its population of around 140 million potential customers, and a pool of highly qualified staff, Russia has long been recognized as an important market for pharmaceutical companies. The pharma market in Russia has shown stable annual growth of 13% to 20% for several ...
By Kim Ribbink • March 28, 2011 -
Talent Pool
Pharmaceutical POOL Steve FRY Dr. Sue MAHONY Lilly Announces Leadership Shifts Lilly has promoted Steve Fry to senior VP of human resources and diversity. Mr. Fry was previously VP of human resources for two of Lilly’s business areas, biomedicines and emerging markets. Mr. Fry succeeds Sue Mahony...
By PharmaVoice Team • March 28, 2011 -
What's New
The INSTITUTE OF CONTINUING HEALTHCARE EDUCATION and healthcare simulation technology developer HUMAN CONDITION HEALTH (HCH) are working together to develop learner-driven continuing medical education (CME) for healthcare professionals with a long-term focus on improving patient outcomes. Throug...
By PharmaVoice Team • March 28, 2011 -
PharmaTrax
Sales, Marketing, and R&D Trends from Industry Analysts Featured Briefs: Pharma Faces Record Patent Expirations Sidebars: Projected U.S. sales of top products going off patent in 2011 Projected U.S. sales of top products going off patent in 2012 New Product Planning Team Key to Launch Success...
By PharmaVoice Team • March 28, 2011 -
UpFront
» Scott Weintraub Honored Scott Weintraub, founding principle of Healthcare Regional Marketing, has been selected for the 2010 Outstanding Leadership Recognition Award by the U.S. Leaders and Entrepreneur’s Association (USLEA). The USLEA Awards Program recognizes highly regarded individuals...
By PharmaVoice Team • March 28, 2011 -
Thought Leaders
Ryan Abbate. President, Pacific Communications, a healthcare communications agency that offers strategic and tactical communications solutions. For more information, visit pacific-com.com. Edward Abrahams, Ph.D. President,The Personalized Medicine Coalition, which brings together the academ...
By PharmaVoice Team • March 7, 2011 -
Around the World in 3,650 Days
Some experts say globalization will be the big story. As companies expand into new geographies to increase their revenue footprint and meet unmet healthcare needs, they will leverage talent wherever it is located to deliver solutions to markets everywhere. “The current model of serving mature mar...
By PharmaVoice Team • March 7, 2011 -
Business Not As Usual
A decade ago, our experts identified the need for pharmaceutical companies to begin to re-evaluate the business model in light of commercialization hurdles, a looming patent cliff, pipeline constrictions, mergers and acquisitions to name just a few game changers. Now, 10 years later some of these...
By PharmaVoice Team • March 7, 2011 -
Agility: Key to Agency Success in the Future
For anybody involved in healthcare advertising, on the agency as well as the client side, the last decade has been marked by myriad changes and market factors that have impacted all aspects of the business. Client mergers and acquisitions, heightened regulatory scrutiny of messaging, more messagi...
By PharmaVoice Team • March 7, 2011 -
A Decade of Change
During the past decade there have been tremendous advances in science, innovation, technology, communications, and patient engagement. There have also been some tremendous setbacks, including major drug recalls, intensified regulatory oversight, and let’s not forget the infamous “gas-and-go" tac...
By Taren Grom • March 7, 2011 -
Last Word
PV: What are some of the challenges facing pharmaceutical companies that technology can address? Kumar: With shrinking drug pipelines, companies are investing in better collaboration, standardization, and analytical tools to improve R&D productivity as well as their sales and marketing opera...
By PharmaVoice Team • March 3, 2011 -
On the Calendar
March 21-22 BioConference Live: Life Sciences PharmaVOICE is exhibiting at this event. BioConference Live, bioconferencelive.com March 21-23 Digital Marketing & Communications for Canadian Pharma Toronto PharmaVOICE subscribers receive a $200 discount; register using keycode PharmaVOICE Adva...
By PharmaVoice Team • March 3, 2011 -
PharmaTrax
Pharmaceutical companies will see an opportunity to increase their visibility with consumers, influence health outcomes, and reduce healthcare costs while increasing revenue using digital strategies and technology, according to Top Health Industry Issues of 2011, a report published by the Pricewa...
By PharmaVoice Team • March 3, 2011 -
Outlet
According to a new study, media coverage of HIV/AIDS fell more than 70% in developed countries over the last two decades. The Trends in Sustainability Project — a joint project of the University of Leeds, Queen’s University Belfast, the Berlin-based Institute for Futures Studies and Technology As...
By PharmaVoice Team • March 3, 2011 -
UpFront
Patent Cliff By 2016 medicines that generate sales of $133 billion for their manufacturers in the U.S. alone will be exposed to generics, including drugs worth $33.2 billion in 2011 that will lose patent protection in 2012, more than double this year’s figure, according to EvaluatePharma Ltd. P...
By PharmaVoice Team • March 3, 2011 -
Reader Feedback
Who Inspires You? PharmaVOICE Wants to Know! Each year the PharmaVOICE 100 is determined by the collective participation of you, our readers. This is your opportunity to recognize the people who inspire and motivate you and others; who are having the greatest influence on corporate leadership, re...
By PharmaVoice Team • March 3, 2011 -
Letter from the Editor
Cheers! Time flies when one is having fun. And the last 10 years have been extremely fun and extremely rewarding. It’s been great getting to know so many of you throughout the life-sciences industry. Back in 2001, the term life-sciences was not common, in fact many questioned us as to what it mea...
By PharmaVoice Team • March 3, 2011 -
SHOWCASE FEATURE: Unclogging the Patient Recruitment Bottleneck
The increased complexity of clinical trial design and the trend toward more targeted patient populations necessitates rethinking the traditional methods of patient recruitment to overcome failure and timeline extensions. Patient recruitment remains to be one of the biggest, and most costly, bott...
By Taren Grom • Jan. 26, 2011 -
M&A: A Short-Term Solution Whose Time May Be Over
2009 was punctuated by the latest and greatest round of major pharmaceutical company mergers, with the big three — Merck and Schering-Plough, Pfizer and Wyeth, and Roche and Genentech — shining a spotlight on M&A practices in the industry. In reality, M&A has always been a growth strategy...
By Robin Robinson • Jan. 26, 2011 -
Developing A True Strategic Partnership
The biopharmaceutical industry is facing intense pressure within research and development to bring new drugs to the market at a time when drug development has become complex and expensive. Blockbuster patent expirations, more complex protocols, increasing R&D costs, patient recruitment issues...
By PharmaVoice Team • Jan. 26, 2011 -
Last Word
PV: What should the goals of a corporate social media program be? Adler: There are many opportunities for companies to engage in social media; generally these fall into three categories. Certainly, chief among the reasons to embark upon a proactive social media program is to enhance awareness amo...
By PharmaVoice Team • Jan. 26, 2011